CB2 Receptor Selective Modulators via Local Quality Structural Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CB2 receptor agonists often exhibit significant CB1 activity, leading to adverse effects, and there is a need for compounds that selectively activate the CB2 receptor with minimized CB1 activity for therapeutic applications such as inflammation and pain treatment.
Innovation Solution
Development of novel compounds with specific structural features that bind to the CB2 receptor, reducing CB1 activity, including specific alkyl, cycloalkyl, and heterocyclic substitutions, and their use in pharmaceutical compositions for therapeutic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB2 receptor agonist compounds are used to treat inflammation and pain, then therapeutic benefits are achieved, but CB1 receptor activation occurs causing adverse effects
Solution Approach 1:
The patent applies local quality by introducing specific substituents at particular positions on the cannabinoid molecule structure. Different substituents (R1-R10) are placed at specific locations to modulate receptor selectivity, ensuring the compound interacts preferentially with CB2 over CB1 receptors while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, chain lengths, and molecular weight within specific ranges. These parameter adjustments optimize the compound's receptor binding profile to achieve high CB2 selectivity while minimizing CB1 activation, directly resolving the technical contradiction.
2Adaptability or versatility
If dual CB1/CB2 agonists are used, then both CB1 and CB2 effects are achieved, but adverse effects increase due to lack of selectivity
Solution Approach 1:
The patent uses local quality by placing specific functional groups at defined positions on the molecular scaffold. This localized structural modification creates steric and electronic properties that favor CB2 binding over CB1, enabling selective activation without requiring dual agonist activity, thus eliminating adverse effects while maintaining versatility.
Solution Approach 2:
The patent applies inversion by designing compounds that achieve therapeutic effects through selective CB2 activation rather than dual CB1/CB2 activation. This inverted approach reverses the conventional strategy of broad-spectrum cannabinoid activity, demonstrating that selectivity can be achieved through careful structural design rather than requiring multiple receptor interactions.
Data Source
Figure 1
Figure 2
AI summary
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.